Pay in 4 interest-free payments of $6.15 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
The Investment Opportunity for Weight Loss Drugs Research forecasts that the GLP-1 market will exceed $130 billion by 2030, driven equally by diabetes and obesity usage
The medication appears to affect central appetite pathways, with GLP-1 receptors found in brain regions responsible for appetite regulation, including the hypothalamus
And for patients with concurrent fatty liver disease, the data is pointing toward a level of efficacy we have not seen before from any medication
Wegovy has been shown to improve several metabolic markers: Reduced blood pressure Improved cholesterol profiles Enhanced insulin sensitivity Decreased inflammation markers These benefits may be particularly valuable for post-cholecystectomy patients with existing metabolic concerns
